Board of Directors

APIM Therapeutics's Board of Directors comprises the following members (in addition to Marit Otterlei).

Erlend Skagseth, MBA, Chairman

Erlend Skagseth is currently the Managing Partner at Sarsia Seed Management AS which manages the Sarsia Seed Fund. Erlend brings 25 years of experience from R&D based IPR, project and business development from Christian Michelsen Research, Forinnova and Sarsia Innovation. He has managed several turnaround processes and negotiated a large number of international contracts, licenses and trade exits. He is also a Board Member in Avexxin, Vaccibody and Geneseque.

Stener Kvinnsland, MD, PhD, Board Member

Dr. Stener Kvinnsland has more than 30 years of experience in oncology. He is currently Chairman of the Board at the Bergen Research Foundation, the Oslo University Hospital and Helse Stavanger Hf. Among Dr. Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan. He was also employed at Oslo Universitetssykehus Hf Chairman) and Health Faculty at Tromso University (Chairman). Dr. Kvinnsland also serves on the Board of BergenBio.

Farzad Abdi-Dezfuli PhD, Board Member

Dr. Abdi-Dezfuli is currently a Partner at Sarsia Seed Management AS. He has a strong background in preclinical and clinical research with extensive drug development experience from Eli Lilly culminating as Team leader medical, Eli Lilly, Norway. He also brings to the Board several years of experience in commercializing innovative medical/biotech projects from the Sarsia investment group. Dr. Abdi-Dezfuli is also serving as a Board Member in Avexxin and as a Board Observer in BergenBio and Vaccibody.

Jørgen André Nilsen, Board Member

Jørgen has more than 18 years of experience in the intersection of entrepreneurship and venture investment. He is an accomplished entrepreneur and the founder of several ICT and energy service companies, both in Norway and the US. He has also worked as an affiliate researcher at the Stanford Research Institute (SRI) Learning on Demand program and worked as a technology advisor for the Norwegian Trade Council in San Francisco. Before joining Televenture Management as partner, he served as Investment Director at the Technology Transfer Office Campus Kjeller AS.

Martin Welschof PhD, Board Member

Dr. Welschof is currently the CEO for BioInvent, Sweden. Martin brings significant senior executive experience in the biotech sector having launched and/or built successful businesses focused on drug development and drug discovery platforms. Before joining BioInvent, Martin Welschof was CEO of Opsona Therapeutics, Managing Director and co-founder of Affitech A/S in Oslo/Norway and Copenhagen/Denmark. Prior to joining Affitech A/S, Dr. Welschof was the Director of Technology at Axaron Bioscience AG, Heidelberg, Germany. During his period at Axaron he worked also in the parent company of Axaron Bioscience, LYNX Therapeutics Inc. in Hayward California. Martin holds a PhD in the field of recombinant antibody technology from the University of Bielefeld, Germany. Martin Welschof also serves at the board of Nextera.

Birgitte Gangmark Villmo, Board Observer

Birgitte Gangmark Villmo is currently representing Investinor, the largest venture fund and investor in APIM Therapeutics, in its Board as a Board Observer. Birgitte has a Master’s degree in Financial Economics from NTNU and a Master of Finance from Massachusetts Institute of Technology (MIT). Prior to her engagement at Investinor, she formerly worked 5 years at Norges Bank Investment Management (NBIM) as a graduate trainee and analyst, mainly in London where she was also seconded to UBS Investment Bank for one year. Before joining Investinor, Birgitte worked for a shorter period at NTNU and for a real estate company in Chile.